Skip to main content

Table 7 The association of antihypertensive drugs with VAF

From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure

Author Design N (Control) Exposure Timing Outcome (duration) VAF development
Gradzki et al [84] Retrospective 121 (96) ACE-I
Various
Primary AVG failure (1 month to 5 years) Lower risk
(HR 0.47, 95% CI 0.23–0.93, P < 0.03)
Sajgure et al [83] Retrospective 266 (142) ACE-I
Various
Time to AVG failure Lower risk
(671 vs. 459 days, P = 0.012)
Jackson et al [85] Retrospective 332 (263) ARB
Various
Primary patency rates of VA (2 years) Lower risk
(AVF: HR 0.35, 95% CI 0.16–0.76, P = 0.08)
(AVG: HR 0.41, 95% CI 0.18–0.95, P = 0.039)
Chen et al [82] Retrospective 42244 (18480) ACE-I
ARB
CCB
Various
Primary patency rates of VA Lower risk
(AVF: HR 0.586 for ACE-I, 0.532 for ARB, 0.485 for CCB)
(AVG: HR 0.557 for ACE-I, 0.536 for ARB, 0.482 for CCB)
  1. VAF vascular access failure, VA vascular access, AVG arteriovenous graft, HR hazard ratio, CI confidential interval